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Clara cells are nonciliated, nonmucous secre-
tory cells localized mostly in the bronchiolar
surface epithelium, and they are one of the
most multifunctional and heterogeneous cell
types in the mammalian lung (1). Clara cells
appear to play a role in pulmonary inflam-
mation and fibrosis in the distal airways by
serving as progenitors of bronchial epithelial
cells (2–5). Clara cells are particularly likely
to undergo apoptosis (6,7) when alveolar
and bronchial epithelial cell apoptosis
induces pulmonary ﬁbrosis (8).
Clara cells are reported to have an
inhibitory effect on pulmonary inﬂammation
and ﬁbrosis. For example, they secrete Clara
cell secretory protein (CCSP) (9), which
inhibits pulmonary inﬂammation (10); sur-
factant proteins, which prevent alveolar col-
lapse (11–15); and protease inhibitors such as
secretory leukocyte protease inhibitor (SLPI)
(16–18) and elafin (17,18). Clara cells can
also promote pulmonary inflammation and
ﬁbrosis. Of the different cell types identiﬁed
in the lung, Clara cells appear to have the
highest level of cytochrome P450 monooxy-
genases (19). Studies have also shown that
the metabolic products of these monooxyge-
nases can damage bronchial epithelial cells
and that most bronchial epithelial cells pro-
duce various chemokines and proinﬂamma-
tory cytokines during bronchial injury
(20–23). Attention has therefore focused on
the balance between the inhibitory and pro-
motional effects of Clara cells in the process
of pulmonary inflammation and fibrosis in
vivo.
Plopper et al. (24–26) and many other
researchers have created a mouse model in
which Clara cells are selectively ablated with
naphthalene, allowing the general role of
Clara cells in pulmonary inﬂammation and
ﬁbrosis to be analyzed in vivo. 
Various factors are involved in pulmonary
inﬂammation and ﬁbrosis. Like free radicals,
matrix-degrading matrix metalloproteinase
(MMP) enzymes directly cause airway and
pulmonary injury and inflammation, but
they also play an important role in repair
(27). Increased expression of MMP-2 and
MMP-9, enzymes that degrade type IV colla-
gen and elastin, major structural components
of the basement membrane, has been
observed in the acute stages of pulmonary
inflammation in animal studies (28).
Expression of these MMPs is also increased
in various types of inflammatory lung dis-
eases in humans, such as bronchiolitis oblit-
erans organizing pneumonia and idiopathic
pulmonary ﬁbrosis (29). These ﬁndings sug-
gest that MMP-2 and MMP-9 are closely
involved in inﬂammation and ﬁbrosis.
In the present study, we investigated the
role of Clara cells in inﬂammation and ﬁbro-
sis in vivo by exposing Clara cell-ablated
mice to crystalline silica, which is known to
cause pulmonary fibrosis (30–33), and
examined the gene expression of MMP-2
and MMP-9 in lung tissue using reverse
transcription-polymerase chain reaction
(RT-PCR).
Materials and Methods
Animals. Male FVB/n mice (8–12 weeks of
age), as described previously (3,34), were
used in the study. Age-matched mice were
purchased from CLEA Japan, Inc. (Tokyo,
Japan).
All of the animals were maintained
according to the Guidelines for Animal
Experimentation of the University of
Occupational and Environmental Health,
Japan, and the Committee on Care and Use
of Laboratory Animals of the Institute of
Laboratory Animal Resources, National
Research Council (Washington, DC, USA).
Creation of Clara cell-ablated mice.
Naphthalene (300 mg/kg body weight) was
obtained from Wako Pure Chemical
Industries, Ltd. (Osaka, Japan), dissolved in
a corn oil vehicle, and injected intraperi-
toneally. Control mice were injected with
vehicle only.
Inhalation of crystalline silica. Crystalline
silica (Min-U-Sil 5 silica; U.S. Silica,
Berkeley Springs, WV, USA) was used in the
study. The mice were housed in an exposure
chamber and exposed to crystalline silica for
6 hr/day, 5 days/week for up to 2 weeks. The
mass concentration of the crystalline silica
was 97.1 ± 9.5 mg/m2 and was measured
gravimetrically at 1-day intervals by the suc-
tion of air through a glass filter. Both the
groups of wild-type mice and that of Clara
cell-ablated mice were exposed to crystalline
silica or fresh air. Each group, composed of
ﬁve animals, was sacriﬁced after 1, 3, 7, and
14 days of exposure. 
Preparation of RNA, cDNA synthesis,
and polymerase chain reaction. RNA was
extracted from the lung using guanidinium
thiocyanate-phenol-chloroform. Total RNA
(0.5 µg) was used to synthesize single-strand
cDNA with Moloney murine leukemia virus-
derived reverse transcriptase (Perkin Elmer,
Norwalk, CT, USA). An equal amount of
cDNA from each sample, standardized to
give identical signals on the gel following
amplification with β -actin primer, was
amplified by specific primers for each gene
(Table 1). The ampliﬁcation was performed
with a Thermocycler (Astech, Fukuoka,
Japan) under the following conditions:
denaturation at 94°C for 45 sec, annealing at
60°C for 45 sec, and extension at 72°C for 2
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We investigated the function of Clara cells in vivo during exposure to inhaled crystalline silica by
examining pulmonary matrix metalloproteinase (MMP)-2 and MMP-9 mRNA levels in mice. The
Clara cells of male FVB/n mice (8–12 weeks old) were ablated by intraperitoneal administration of
naphthalene (300 mg/kg) in a corn oil vehicle. The mice were then exposed to crystalline silica
(Min-U-Sil-5 silica, 97.1 ± 9.5 mg/m2, 6 hr/day, 5 days/week) for up to 2 weeks. Transcriptional
levels of mRNA extracted from the lungs were assessed by reverse transcription-polymerase chain
reaction. Gene expression of both MMP-2 and MMP-9 was significantly more marked in the
Clara cell-ablated group than in the group with Clara cells, indicating that Clara cells inhibit
MMP expression. Our ﬁndings suggest that Clara cells inhibit pulmonary inﬂammation induced
by crystalline silica via MMPs in vivo. Key words: Clara cell, crystalline silica, matrix metallopro-
teinase, naphthalene, reverse transcription-polymerase chain reaction. Environ Health Perspect
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min for MMP-2, MMP-9, and β -actin genes.
β -actin was coampliﬁed as an internal stan-
dard in a quantitative polymerase chain reac-
tion (PCR) ampliﬁcation of mRNA. 
The fragment amplified by PCR was
detected by electrophoresis on a 2% agarose
gel with DNA markers and was visualized
by ethidium bromide staining. The gels
were photographed with Polaroid Type 665
positive/negative film (Polaroid Corp.,
Cambridge, MA, USA) under ultraviolet
light at identical exposure and development
times. The bands of the positive film were
scanned, and the density of each PCR prod-
uct was measured using National Institutes
of Health (NIH) Image 1.61 software (writ-
ten by Wane Rasband, National Institutes of
Health, Bethesda, MD, USA). To quantify
the transcriptional level of mRNA, the data
were normalized to represent equivalent
RNA loading based on the density of the β -
actin product at the appropriate cycle of a
given gene product. 
Statistical analysis. Values are expressed
as the mean ± standard error. We assessed
the difference between values using the
Mann-Whitney U test. p-Values < 0.05 were
considered signiﬁcant. 
Histopathology and immunohistochem-
istry. The inﬂation-ﬁxed lungs from the mice
were washed in phosphate-buffered saline
(PBS) three times and ﬁxed in 10% buffered
formalin. Parafﬁn-embedded specimens were
sectioned at 5 µm and stained with hema-
toxylin and eosin for morphologic analysis by
microscopy. For immunohistochemical stain-
ing for MMP-2 and MMP-9, the tissue sec-
tions were deparaffinized by washing in
xylene four times for 10 min per wash, fol-
lowed by dehydration through a series of
100% to 70% ethanol washes. The slides
were placed in methanol containing 0.5%
hydrogen peroxide to block endogenous per-
oxidase activity. Nonspecific binding was
blocked by incubating the slides 0.1M-PBS
for 1 hr at room temperature.
We incubated the lung sections overnight
at 4°C with either afﬁnity-puriﬁed goat poly-
clonal antibodies specific for MMP-2 and
MMP-9 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA; both at dilutions of
0.4 µg/mL) or rabbit anti-rat polyclonal anti-
serum specific for CCSP (courtesy of
Gurmukh Singh, University of Pittsburgh
School of Medicine, Pittsburgh, PA, USA;
diluted 1:500–1:1000 before use).The sec-
tions were rinsed ﬁve times in 0.1 M PBS and
incubated for 30 min at room temperature
with biotinylated anti-goat secondary anti-
body made in rabbits (Vector Laboratories
Inc., Burlingame, CA, USA) for MMP-2 and
MMP-9, and anti-rabbit secondary antibody
(DAKO JAPAN Co., Ltd., Kyoto, Japan) for
CCSP, then incubated with avidin-biotin
complex (DAKO JAPAN Co., Ltd.) for 30
min at room temperature. Sections were
washed with PBS, rinsed briefly in 0.1 M
acetate buffer (pH 6.0), incubated with
diaminobenzidine for 3 min, and counter-
stained with hematoxylin. Incubations were
carried out without the primary or secondary
antibody as a labeling control.
Results
Immunohistochemistry for CCSP. Figure 1
shows that immunostaining patterns for
CCSP 14 days after the intraperitoneal injec-
tion of naphthalene (Figure 1B) or corn oil
vehicle only (Figure 1A) to the silica nonex-
posed group. The Clara cells were most
ablated 3 days after the exposure (data not
shown), and Figure 1B shows that > 70% of
ablation continued 14 days after the expo-
sure. Clara cells remained at the bifurcation
of the bronchiole throughout the period.
MMP-2. The results for MMP-2 are
shown in Figure 2. There was no difference
in expression of MMP-2 between the unex-
posed groups of wild-type mice and that of
Clara cell-ablated mice. MMP-2 expression
was increased in both the Clara cell-ablated
and nonablated groups exposed to crystalline
silica, and comparison of these groups
showed that the MMP-2 expression tended
to be higher in the Clara cell-ablated group
from the 3-day exposure and that the
increase was statistically significant after 7
and 14 days of exposure.
MMP-9. The results for MMP-9 are
shown in Figure 3. There was no difference
in expression of MMP-9 between the unex-
posed groups of wild-type mice and that of
Clara cell-ablated mice. In the two crystalline
silica-exposed groups, the MMP-9 expression
increased after 7 days of exposure and was
statistically signiﬁcantly higher in the Clara
cell-ablated group than in the group of mice
with Clara cells after 14 days of exposure.
Histopathology and immunohistochem-
istry. Histopathologic examination using
hematoxylin and eosin staining revealed an
increase in macrophage numbers after expo-
sure in both the Clara cell-ablated and the
nonablated groups. Of the two groups
exposed, foamy macrophages were seen in the
Clara cell-ablated group but not in the non-
ablated group (data not shown). No marked
accumulation of crystalline silica was evident.
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Figure 1. Immunohistochemistry for CCSP. (A) Mouse with Clara cells 14 days after intraperitoneal injection
of corn oil vehicle only. (B) Clara cell-ablated mouse 14 days after intraperitoneal injection of naphthalene.
Bar = 50 µm.
Table 1. Oligonucleotides of primers of target genes.
PCR product
mRNA species mRNA Cycle bp
MMP-2 (sense) 5’-GAGATCTGCAAACAGGACAT 26 476
(antisense) 5’-GGTTCTCCAGCTTCAGGTAA
MMP-9 (sense) 5’-CGACGAGTTGTGGTCGCTGG 33 624
(antisense) 5’-GCACGCTGGAATGATCTGAG
β -actin (sense) 5’-ATCATGTTTGAGACCTTCAACACC 22 357
(antisense) 5’-TAGCTCTTCTCCAGGGAGGImmunostaining revealed the expression
of MMP-2 and MMP-9 in alveolar
macrophages, bronchial epithelial cells, alveo-
lar epithelial cells, and vascular endothelial
cells in both the Clara cell-ablated and the
nonablated groups. The alveolar macrophages,
bronchial epithelial cells, and vascular
endothelial cells were particularly strongly
stained (Figure 4). However, no newly
strongly stained cell types were found after
both crystalline silica exposure or Clara cell
ablation.
Discussion
We ablated the Clara cells in mice using the
cytoselective toxicity of the metabolic prod-
ucts of naphthalene mediated by cytochrome
P450 monooxygenase (3,24,25,34). In a mor-
phologic study of murine lungs using trans-
mission electron microscopy, Plopper and
colleagues (24–26) reported that intraperi-
toneally administered naphthalene is speciﬁ-
cally toxic to Clara cells and does not cause
changes in other epithelial cells, indicating
that the toxicity of naphthalene to Clara cells
is cytoselective.
Stripp et al. (34) reported that treatment
with naphthalene at a concentration of 300
mg/kg results in the ablation of Clara cells in
the bronchiolar region for at least 20 days in
FVB/n mice (34), which seem to be more
susceptible to naphthalene than do other
mouse strains (35). Using the same method,
we also confirmed that Clara cells are
removed 1 day after naphthalene treatment
and remain absent for at least 2 weeks
(Figure 1B). The Clara cell-ablated mice
were therefore exposed to crystalline silica
for 2 weeks after naphthalene treatment.
In this study, the mice were exposed to a
higher concentration of crystalline silica than
in humans to investigate the role of Clara
cells in the acute inﬂammatory response. We
previously reported marked inflammatory
cell accumulation and silica deposition in the
lungs after intratracheal instillation of 2 mg
crystalline silica in rats (36). The present
histopathology findings using hematoxylin
and eosin staining and phase-contrast
microscopy of the lungs revealed an increase
in inﬂammatory cell numbers in the alveoli,
but showed no excessive deposition of crys-
talline silica in the lungs as was seen in our
previous study. Although different animal
species were used in the two studies, in the
present study it was estimated that < 2 mg of
crystalline silica was deposited in the lungs
after inhalation, suggesting that this dose
might not be excessive. In long-term inhala-
tion studies conducted to date, we found
that the maximum amount of dust deposited
in the lungs is approximately 2 mg regardless
of particle type (37).
In the current study, gene expression of
MMP-2 and MMP-9 in the lungs tended to
increase after crystalline silica exposure. We
are the ﬁrst to investigate MMPs induced by
inhaled crystalline silica. Increased MMP-2
and MMP-9 expression was observed in
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Figure 2. (A) Ethidium bromide staining of the PCR products separated on 2% agarose gel of MMP-2 mRNA in the lungs of crystalline silica-exposed and nonexposed
mice. (B) Effect of crystalline silica exposure and the ablation of Clara cells on the expression of MMP-2 mRNA. Expression was signiﬁcantly greater in the group of
mice with Clara cells. The results are expressed as the ratio of MMP-2 to β -actin (mean ± SEM). M, DNA marker φ X174/Hae III). 
*Signiﬁcantly different from the group of mice with Clara cells (p < 0.05). 
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Figure 3. (A) Ethidium bromide staining of the PCR products separated on 2% agarose gel of MMP-9 mRNA in the lungs of crystalline silica-exposed and nonexposed
mice. (B) Effect of crystalline silica exposure and the ablation of Clara cells on the expression of MMP-9 mRNA. Expression was signiﬁcantly greater in the group of
mice with Clara cells. The results are expressed as the ratio of MMP-9 to β -actin (mean ± SEM). M, DNA marker φ X174/Hae III). 
*Signiﬁcantly different from the group of mice with Clara cells (p < 0.05).
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Clara cell-ablatedexperimental silicosis induced by intratra-
cheal instillation of crystalline silica in rats
(38) and also in a previous study we con-
ducted (36); both reflect the results of the
present study.
Our current results show that Clara cells
inhibit gene expression of MMP-2 and
MMP-9 in vivo after crystalline silica expo-
sure. In addition to producing factors that
appear to stimulate MMPs expression, such
as phospholipases (22,39), proinﬂammatory
cytokines (40,41), and chemokines (42,43),
bronchial epithelial cells, including Clara
cells, also produce factors that inhibit MMPs
expression, such as CCSP, SLPI (16–18),
and elafin (17,18). However, our results
confirm that Clara cells generally inhibit
MMPs, although it is unclear which factors
are responsible for this inhibition. 
It is possible that CCSP produced speciﬁ-
cally by Clara cells plays some part. Szabo et
al. (44) reported a marked reduction in
MMP-2 and MMP-9 expression in A549 cells
in which CCSP was overexpressed. In the pre-
sent study, immunohistologic examination
showed that MMPs are produced mainly in
alveolar macrophages, bronchial epithelial
cells, and alveolar epithelial cells, and that
CCSP secreted from Clara cells may inhibit
the production of MMPs from these cells.
It is also possible that protease inhibitors
produced by Clara cells are involved in the
inhibition of MMPs. The two types of pro-
tease inhibitors produced in Clara cells, SLPI
(16–18) and the elastase-specific inhibitor
elafin (17,18), have an antiinflammatory
effect. Studies have shown that SLPI and
elafin inhibit MMP-2 and MMP-9 (45),
suggesting that these protease inhibitors
secreted by Clara cells may have inhibited
the expression of MMP-2 and MMP-9 in
our study.
In summary, we investigated gene expres-
sion of MMP-2 and MMP-9 in the lungs
after inhalation of crystalline silica in mice in
which the Clara cells had been ablated with
naphthalene. Gene expression of MMP-2
and MMP-9 was signiﬁcantly more marked
in the Clara cell-ablated group than in the
mice with Clara cells, indicating that Clara
cells inhibited MMP-2 and MMP-9 expres-
sion. Our findings suggest that Clara cells
inhibit pulmonary inﬂammation and ﬁbrosis
via MMPs in vivo.
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Figure 4. Immunohistochemistry for MMP-2 and MMP-9. (A) Immunohistochemistry for MMP-2 in the lung of
a mouse with Clara cells exposed to crystalline silica for 14 days. (B) Immunohistochemistry for MMP-2 in
the lung from a Clara cell-ablated mouse exposed to crystalline silica for 14 days. (C) Immunohistochemistry
for MMP-9 in the lung from a mouse with Clara cells exposed to crystalline silica for 14 days. (D)
Immunohistochemistry for MMP-9 in the lung from a Clara cell-ablated mouse exposed to crystalline silica
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